Análises de mutações no gene JAK2 em pacientes com diagnóstico clínico de Policitemia Vera atendidos em um único centro da cidade de Juiz de Fora
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora
DOI
Abstract
Myeloproliferative neoplasms (MPN) are caused by a clonal proliferation of a
hematopoietic progenitor. First described in 1951 as “Myeloproliferative Diseases”
and reevaluated by the World Health Organization in 2011 (WHO, 2011), the
Myeloproliferative Neoplasms gather the Polycythemia Vera, Essential
Thrombocythemia and Primary Mielofibrose in a subgroup called negative BCR-ABL.
According to WHO the revised diagnosis criteria for myeloproliferative neoplasms,
the presence of JAK2 V617F mutation, is considered the most important criterion for
the diagnosis of negative BCR-ABL subgroup representing a clonal marker. The
Polycythemia Vera is primarily diagnosed by an independent stimulating factor in red
cells mass increasing, followed by an increase of leukocytes in peripheral blood,
spleen and thrombocytosis. It usually occurs in men and women of all age groups
with higher incidence in 60-year-old patients ranging from 0.7 to 2.6/ 100.000
hab/year. The V617F mutation in the JAK2 gene produces an altered protein that
activates constitutively the JAK-STAT pathway and other pathways downstream as a
result the protein transcriptional activation and signal transduction (STAT) are
subsequently phosphorylated causing impact in the expression of genes involved in
regulation of apoptosis and regulatory proteins, as well as altering the rate of
proliferation of hematopoietic cells. In this study 26 patients with Polycythemia Vera
were selected in Juiz de Fora, Minas Gerais. The peripheral blood was used for
genetic material isolation (JAK2 mutation). The clinical data of each patient were
related to each other and correlated with the molecular data.
Description
Citation
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
